Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.

导出 OA

翻译打印收藏纠错

第一作者： Petra,Kolenc Peitl

第一单位： Deparment of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.

作者： Petra,Kolenc Peitl ^[1] ; Christine,Rangger ^[2] ; Piotr,Garnuszek ^[3] ; Renata,Mikolajczak ^[3] ; Alicja,Hubalewska-Dydejczyk ^[4] ; Theodosia,Maina ^[5] ; Paola,Erba ^[6] ; Clemens,Decristoforo ^[2]

作者单位： Deparment of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia. ^[1] Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria. ^[2] Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland. ^[3] Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland. ^[4] Molecular Radiopharmacy, INRASTES, NCSR "Demokritos", Athens, Greece. ^[5] Nuclear Medicine, Department of Translational Research and New Technologies in Medicine University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. ^[6]

关键词 111In-CP04 clinical trial peptide radiopharmaceuticals regulatory framework theranostics nuclear medicine

主题词动物(Animals);文献工作(Documentation);人类(Humans);质量控制(Quality Control);放射性药物(Radiopharmaceuticals);社会控制, 正式(Social Control, Formal)

DOI 10.1002/jlcr.3712

PMID 30741441

发布时间 2021-12-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交